Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose plasma and CSF pharmacokinetics study of CAD-1883 in healthy volunteers
NL-OMON47994Completed
- Sponsor
- Cadent Therapeutics
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of rimtuzalcap in spinocerebellar ataxia (SCA) and essential tremor (ET), sponsored by Cadent Therapeutics. Primary endpoints: Plasma pharmacokinetic parameters of CAD-1883 and Cerebrospinal fluid pharmacokinetic parameters of CAD-1883. Started Oct 2019; status: completed.
02
Drugs
rimtuzalcap
03
Conditions
spinocerebellar ataxia (SCA)essential tremor (ET)
Beyond the preview
Go deeper on NL-OMON47994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47994.